Emmanuel S. Antonarakis, M.D.
Johns Hopkins University
H-index: 77
North America-United States
Top articles of Emmanuel S. Antonarakis, M.D.
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer | npj Genomic Medicine | Hannah E Bergom Laura A Sena Abderrahman Day Benjamin Miller Carly D Miller | 2024/1/22 |
Differences in genomic, transcriptomic, and immune landscape of prostate cancer (PCa) based on site of metastasis (mets). | Umang Swami Shayan Nazari Georges Gebrael Andrew Elliott Aditya Bagrodia | 2024/2/1 | |
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide | Clinical Cancer Research | Susan Halabi Siyuan Guo Joseph J Park David M Nanus Daniel J George | 2024/2/13 |
The opposing effects of Class 1B and Class 2 FOXA1 mutations in prostate cancer. | Justin Hwang Sachin Deshmukh Sharon Wu Andrew Elliott Nishant Gandhi | 2024/2/1 | |
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer | Neal Shore Emmanuel Antonarakis Ashley Ross Catherine Marshall Kelly Stratton | 2024/3/2 | |
Dissemination of circulating tumor cells in breast and prostate cancer: Implications for early detection | Song Yi Bae Kaylee Judith Kamalanathan Catalina Galeano-Garces Badrinath R Konety Emmanuel S Antonarakis | 2024/4 | |
MP01-16 MOLECULAR DRIVERS OF ORGANOTROPISM AND CISPLATIN RESISTANCE IN GERM CELL TUMORS | Journal of Urology | Margaret F Meagher Yun Cheng Sawa Liwei Jia Frederick Millard Harris Krause | 2024/5/1 |
BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone+ olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing … | Maha HA Hussain Masha Kocherginsky Neeraj Agarwal Nabil Adra Jingsong Zhang | 2024/2/1 | |
Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer | 2024/1/9 | ||
Survival outcomes in patients (pts) with prostatic cancer (PCa) based on pathologically confirmed sites of metastasis. | Gliceida Galarza Fortuna Shayan Nazari Umang Swami Andrew Elliott Georges Gebrael | 2024/2/1 | |
Pan-Cancer Interrogation of MUTYH Variants Reveals Biallelic Inactivation and Defective Base Excision Repair Across a Spectrum of Solid Tumors | JCO Precision Oncology | Channing J Paller Hanna Tukachinsky Alexandra Maertens Brennan Decker Julian R Sampson | 2024/2 |
Radiotheranostics in advanced prostate cancer: current and future directions | Angela Y Jia Ana P Kiess Qiubai Li Emmanuel S Antonarakis | 2024/3 | |
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers | Nature Cancer | Maishara Muquith Magdalena Espinoza Andrew Elliott Joanne Xiu Andreas Seeber | 2024/3/25 |
The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors | Sandra Jones Harris Benjamin Krause Jose Noy Samuel A Kareff Asaad Trabolsi | 2023/6/1 | |
Case Series of Men with the Germline APC I1307K variant and Treatment-Emergent Neuroendocrine Prostate Cancer | Clinical Genitourinary Cancer | Minas P Economides Mari Nakazawa Jonathan W Lee Xiaochun Li Lucas Hollifield | 2024/2/1 |
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial | Nature communications | Mark C Markowski Mary-Ellen Taplin Rahul Aggarwal Laura A Sena Hao Wang | 2024/1/2 |
Muscadine grape skin extract in men with biochemically recurrent prostate cancer: A phase III, randomized, multicenter, placebo-controlled clinical trial. | Adel Mandl Marianna Zahurak Karen Sfanos Nicole Metri Benjamin L Maughan | 2024/2/1 | |
Homologous recombination repair (HRR) alterations may be passenger events in patients with advanced prostate cancer (PC) with high tumor mutational burden (hTMB). | Vineel Bhatlapenumarthi Navonil De Sarkar Anannya Patwari Emmanuel S Antonarakis Ariel Ann Nelson | 2024/2/1 | |
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes | Prostate Cancer and Prostatic Diseases | Nicholas A Zorko Allison Makovec Andrew Elliott Samuel Kellen John R Lozada | 2024/2/28 |
Tissue-specific thresholds and microenvironment correlates of tumor mutation burden associated with immunotherapy benefit and prognosis in microsatellite stable cancers | Cancer Research | Maishara Muquith Magdalena Espinoza Andrew Elliott Joanne Xiu Andreas Seeber | 2024/3/22 |
Co-Authors
